Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Bone: Enchondroma

Written2008-07Twinkal C Pansuriya, Judith VMG Bovée
Dept of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
Updated2018-03Tessa AH Wilpshaar, Judith VMG Bovée
Dept of Pathology, Leiden University Medical Center, P.O Box 9600 2300 RC Leiden, The Netherlands. T.A.H.Wilpshaar@lumc.nl; J.V.M.G.Bovee@lumc.nl

(Note : for Links provided by Atlas : click)

Abstract

Abstract Review on Enchondroma, with data on clinics, and the genes involved.

Identity

ICD-Topo C400-C403,C408-C414,C418-C419 BONES & JOINTS
ICD-Morpho 9220/0 Enchondroma
Atlas_Id 5333
Phylum Bones::Chondroma
Other namesSolitary enchondroma
Central chondroma
Note Enchondroma is a common benign hyaline cartilaginous neoplasm that develops within the medullary cavity of bone. As the name suggests, it is located within the bone, either centrally (80% of cases) or eccentric (20% of cases). The most commonly affected bones in order of frequency are the phalanges of the hand, humerus, tibia and femur. . Enchondromas are very uncommon in flat bones such as the pelvis, ribs, scapula sternum or vertebrae. Enchondromas are mostly found in the diaphyseal or meta-diaphyseal region of the long bones while they are rarely observed in the epiphysis. . Thirty-five percent of enchondromas develop in the hand whereas its malignant counterpart is extremely rare at this location. In general, malignant transformation of enchondroma is extremely rare (overall risk <1% of cases). In rare instances, multiple enchondromas are found to occur in a syndrome ( enchondromatosis). At gross specimen the enchondroma tissue looks white-grey and opalescent while yellow or red foci represent areas of calcification or ossification.

Clinics and Pathology

Phenotype / cell stem origin Since many cartilaginous tumors develop from the medullar region of the bone, mesenchymal stem cells (MSCs) located in the bone marrow are currently considered the cell-of-origin for enchondroma. MSCs are stem cells that have the ability to differentiate into cells of the adipocytic, osteogenic and chondrogenic lineage. The initiating event of enchondroma development was identified after the observation that patients with multiple enchondromas are also at risk of developing other, unrelated, types of cancer like glioma and acute myeloid leukaemia and the finding that mutations in isocitrate dehydrogenase 1 or 2 (IDH1/2) are frequently found in these types of cancer. Therefore, cartilaginous tumors were also investigated for the occurrence of mutations in these genes. Indeed, in 87% of enchondromas in patients with enchondromatosis and in 52% of solitary enchondromas mutations in IDH1 or -2 were found, pointing to this mutation as an early and crucial event in enchondroma development. Further evidence for a causative role of these mutations came from research showing increased chondrogenic and decreased osteogenic differentiation of MSCs upon treatment of MSCs from different donors with the oncometabolite D-2-hydroxyglutarate, the product of IDH mutations. Likewise, introduction of the most common IDH mutation found in enchondroma into MSCs promoted chondrogenic differentiation, while inhibiting osteogenic differentiation.
Epidemiology Enchondroma accounts for 10-25% of all benign tumours. Both sexes are equally affected and it shows a wide age range from 5-80 years, although the majority of patients present within the second to fifth decade of life.
Clinics The differential diagnosis between enchondroma and low grade chondrosarcoma is difficult and is therefore based on a combination of clinical, radiological and histological parameters. Usually, enchondromas of the long bones are asymptomatic and detected incidentally after a fracture or bone scans for other reasons. In case of long bones, calcified enchondromas can be found. In contrast, enchondromas of the small bones of the hands and feet lack the calcification and may give palpable swellings, with or without pain. Enchondromas can be easily observed in radiographs since normal bone is replaced by mineralized or unmineralized hyaline cartilage. Radiographically, enchondromas are lytic lesions mostly in the center of the bone, can be mildly expansile with well defined, minimally thickened bony margins, along with intralesional calcification and diaphyseal expansion. There is evidence of cartilaginous matrix (rings and arcs or popcorn-like calcifications).
 
Frontal radiograph of the right hand reveals a lytic lesion in the fourth proximal phalanx (yellow arrow) with subtle areas of calcified matrix within the lesion compatible withn an enchondroma. Picture from: http://www.radiologypics.com.
Pathology Macroscopically, most enchondromas are <5 cm in size. The tissue is grey-white and opalescent. Gritty, yellow and red foci represent areas of calcification and ossification, respectively.Microscopically, enchondromas are hypocellular, avascular tumours with abundant hyaline cartilage matrix. The nuclei are small and round with condensed chromatin. Occasionally, binucleated cells without cytologic atypia are found. There is no mitotic activity. Myxoid matrix and endosteal erosion can be present in phalangeal tumors. There is often encasement (deposition of bone at the edges of the lobuli), while entrapment of preexisting host bone is absent and should be regarded a sign of progression to atypical cartilaginous tumour.
More worrisome histological criteria such as increased cellularity, myxoid change, cytological atypia and nuclear hyperchromasia are only tolerated in case of 1) location in the small bones of the hands and feet, 2) in the context of enchondromatosis, 3) in young patients in which the growth plates are still open.
 
Cartilaginous tumour with very low cellularity and abundance of chondroid matrix. Atypical cells and mitoses are absent.
Treatment A wait-and-see policy is justified for asymptomatic lesions considered benign at radiography. Tumor growth can be determined clinically and by means of periodic radiographic examination. Biopsy can be done when asymptomatic lesions become large and symptomatic. Large or symptomatic tumours or borderline cases in which the distinction with low grade chondrosarcoma can not be made histologically nor radiographically can be treated surgically with margin improvement by means of phenol or cryosurgery. Recurrence of enchondroma is highly uncommon after curettage.
Evolution Malignant transformation of solitary enchondroma is extremely rare (<1%). In the context of enchondromatosis ( Ollier disease, Maffucci syndrome ) the risk of malignant transformation is increased up to 40%, depending on their location. While enchondromas are most common at the phalangeal bones, chondrosarcoma of the phalanges is extremely rare. Local recurrence is uncommon, although occasionally an enchondroma will recur many years later, but rarely as an atypical cartilaginous tumor or low-grade chondrosarcoma.
Prognosis Enchondroma is a benign lesion. Recurrence is highly uncommon after curettage. Progression towards malignancy is rare (<1%), unless in the context of enchondromatosis (up to 40%). Pain, extensive endosteal erosion , cortical thickening, bone expansion and large size (>5 cm) could indicate malignant transformation. Only those tumors that cause symptoms such as increase in size, pain or swelling should be further investigated and treated.

Genetics

Note Enchondroma is associated with heterozygous gain-of-function mutations in the genes for IDH1 or IDH2 (isocitrate dehydrogenase 1 (2q34) or 2 (15q26.1)). In 86% of enchondromas in enchondromatosis patients and in 52% of solitary enchondromas mutations in these genes have been found, as described above.
IDH1 mutations are more frequent than IDH2 mutations in enchondroma, with R132C representing the most common mutation in cartilaginous tumors, followed by R132H.
The normal function of IDH is in the TCA cycle, where it catalyzes the conversion of isocitrate into alpha-ketoglutarate. In the case of an IDH mutation, however, the enzyme converts alpha-ketoglutarate into D-2-hydroxyglutarate (D-2-HG), which is considered an oncometabolite. D-2-HG and alpha-ketoglutarate are structurally similar, causing D-2-HG to compete with alpha-ketoglutarate for binding to alpha-ketoglutarate-dependent enzymes. Most of these enzymes are involved in epigenetic regulation and examples include Jumonji-C domain-containing histone demethylases and the TET family of 5-methylcytosine hydroxylases. Inhibition of these enzymes due to binding of D-2-HG results in DNA hypermethylation and histone modifications. Indeed, increased levels of D-2-HG and DNA hypermethylation have been found in enchondromas with IDH1/2 mutations. Another group of alfa-ketoglutarate-dependent enzymes are the prolylhydroxylases, enzymes that promote degradation of HIF1A (hypoxia-inducible factor 1α). Indeed, IDH mutations, via an increase in D-2-HG, have been shown to lead to a stabilization of HIF1A, which in turn results in the stimulation of angiogenesis, an important feature of cancer.
Interestingly, it was shown that while IDH1/2 mutations may be crucial for initial enchondroma development, they are not essential anymore after progression towards chondrosarcoma has occurred. It is likely that other mutations occur, facilitating chondrosarcoma growth.

Bibliography

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM
J Pathol 2011 Jul;224(3):334-43
PMID 21598255
 
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, Aston W, Green CL, Gale RE, Tirabosco R, Futreal A, Campbell P, Presneau N, Flanagan AM
Nat Genet 2011 Nov 6;43(12):1262-5
PMID 22057236
 
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets
Bovée JV, Hogendoorn PC, Wunder JS, Alman BA
Nat Rev Cancer 2010 Jul;10(7):481-8
PMID 20535132
 
Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma
Herget GW, Strohm P, Rottenburger C, Kontny U, Krau T, Bohm J, Sudkamp N, Uhl M
Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up Neoplasma
PMID 24645839
 
Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes
Jin Y, Elalaf H, Watanabe M, Tamaki S, Hineno S, Matsunaga K, Woltjen K, Kobayashi Y, Nagata S, Ikeya M, Kato T Jr, Okamoto T, Matsuda S, Toguchida J
PLoS One 2015 Jul 10;10(7):e0131998
PMID 26161668
 
Maffucci's syndrome: functional and neoplastic significance
Lewis RJ, Ketcham AS
Case report and review of the literature J Bone Joint Surg Am
PMID 4586088
 
Lucas DR, Bridge JA
(2013). Chondromas: enchondroma, periosteal chondroma in Fletcher C. D.M., Bridge J.A., Hogendoorn P., Mertens F (Eds.), WHO Classification of Tumours of Soft Tissue and Bone (pp. 252-254), Lyon: IARCE
 
The origins of osteochondromas and enchondromas
Milgram JW
A histopathologic study Clin Orthop Relat Res
PMID 6600991
 
Comparative genomic hybridization in cartilaginous tumors
Ozaki T, Wai D, Schäfer KL, Lindner N, Böcker W, Winkelmann W, Dockhorn-Dworniczak B, Poremba C
Anticancer Res 2004 May-Jun;24(3a):1721-5
PMID 15274346
 
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovée JV
Nat Genet 2011 Nov 6;43(12):1256-61
PMID 22057234
 
Differential expression of runx2 and Indian hedgehog in cartilaginous tumors
Park HR, Park YK
Pathol Oncol Res 2007;13(1):32-7
PMID 17387386
 
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms
Sandberg AA, Bridge JA
Cancer Genet Cytogenet 2003 May;143(1):1-31
PMID 12742153
 
Evidence of an association between 6q13-21 chromosome aberrations and locally aggressive behavior in patients with cartilage tumors
Sawyer JR, Swanson CM, Lukacs JL, Nicholas RW, North PE, Thomas JR
Cancer 1998 Feb 1;82(3):474-83
PMID 9452264
 
Obstructed labour
Turner M
Nurs Mirror Midwives J 1974 May 31;138(11):74-5
PMID 4494954
 
Cryosurgery in aggressive, benign, and low-grade malignant bone tumours
Veth R, Schreuder B, van Beem H, Pruszczynski M, de Rooy J
Lancet Oncol 2005 Jan;6(1):25-34
PMID 15629273
 
Repair of a cryptotic ear with a trefoil flap: case report
Wesser DR
Plast Reconstr Surg 1972 Aug;50(2):192-3
PMID 4558118
 
Structural and functional changes in Novikoff hepatoma mitochondria
White MT, Tewari KK
Cancer Res 1973 Jul;33(7):1645-53
PMID 4352794
 
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y
Science 2009 Apr 10;324(5924):261-5
PMID 19359588
 

Citation

This paper should be referenced as such :
Wilpshaar TAH, Bovée JVMG
Bone: Enchondrom
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Tumors/EnchondromaID5333.html
History of this paper:
Pansuriya, TC ; Bovée, JVMG. Bone: Enchondroma. Atlas Genet Cytogenet Oncol Haematol. 2009;13(7):519-523.
http://documents.irevues.inist.fr/bitstream/handle/2042/44526/07-2008-EnchondromaID5333.pdf


Other genes implicated (Data extracted from papers in the Atlas) [ 1 ]

Genes IDH2

External links

arrayMap Topo ( C40,C41) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseBone: Enchondroma
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 5 17:06:09 CEST 2018


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.